Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860301 | 0.89 | MEN1 (0.67) | EPHX2NR1H4RAB9ANPC1HDAC3 | |
| SCHEMBL14860245 | 0.86 | EPHX2 (0.54) | EPHX2NR1H4RAB9ANPC1MAPT | |
| SCHEMBL14859138 | 0.85 | NR1H4 (0.52) | EPHX2NR1H4RAB9ANPC1MAPT | |
| SCHEMBL14859889 | 0.84 | SMN1; SMN2 (0.56) | RAB9ANPC1HDAC6MEN1KMT2A | |
| SCHEMBL14859532 | 0.82 | NR1H4 (0.50) | EPHX2NR1H4RAB9ANPC1HDAC3 | |
| SCHEMBL14860135 | 0.80 | HPGD (0.50) | EPHX2NR1H4RAB9ANPC1MAPT | |
| SCHEMBL14859888 | 0.80 | NR1H4 (0.51) | EPHX2NR1H4RAB9ANPC1MAPT | |
| SCHEMBL14859828 | 0.78 | MMP13 (0.47) | NR1H4RAB9ANPC1MAPTCYP1A2 | |
| SCHEMBL14859860 | 0.77 | EPHX2 (0.49) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL14859225 | 0.76 | RAB9A (0.67) | EPHX2NR1H4RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | claimed |
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | UGP2, TPMT, UPP1 | EPHX2 2141/4885NR1H4 4314/4885RAB9A 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.